Translating extraordinary scientific and technological advances occurring in medical research laboratories into providing exceptional care for our patients.
Our current clinical trials are looking at new ways to prevent, detect, or treat disease leading to lifesaving cures.
- AD: Stemedica Cell Technologies’ protocol STEM105-M-AD: A phase 2A, multi-center, randomized, single-blind, placebo-controlled, crossover study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of allogeneic human mesenchymal stem cells to subjects with mild to moderate dementia due to Alzheimer’s disease
- AD: Novel approaches to diagnosing Alzheimer’s disease & predicting progression
- MCI: Mobile technology-based simultaneous aerobic exercise and memory training intervention for older adults with mild cognitive impairmentMCI: Movement based cognitive training program to improve memory functioning in patients with subjective memory concerns or mild cognitive impairment
- Investigating exercise-induced neuroplasticity and its mechanisms in Parkinson’s disease: Targeting executive function and brain circuitry
- Virtual reality-based movement assessment in Parkinson’s patients
- Movement-based cognitive training program to improve memory functioning in patients with Parkinson’s disease
- STROKE: John Wayne Cancer Institute’s JWCI-18-0701: Expanded access treatment protocol of a single intravenous dose of allogeneic mesenchymal bone marrow cells for subjects with neurologic disorders
- STROKE: Microtransponder’s protocol MT-St-03: A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)
- STROKE: Bioness’s protocol STMR-PAIN-002_PSSP: StimRouter™ Neuromodulation System: Implanted peripheral nerve stimulation for pain management when treating patients with chronic post-stroke shoulder pain
- STROKE: Sunovion & Sanbio’s protocol SB-STR02: A double-blind, controlled phase 2B study of the safety and efficacy of modified stem cells (SB623) in patients with chronic motor deficit from ischemic stroke
- TBI: Sanbio’s protocol TBI-01:A double-blind, controlled phase 2 study of the safety and efficacy of modified stem cells (SB623) in patients with chronic motor deficit from traumatic brain injury
If you wish to participate in any of our current studies or if you are interested in a research study but don’t currently see one that suits you, please join our research registry to be placed on a list for future studies.